Search
Search Results
##search.searchResults.foundPlural##
-
THE BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS INFECTION.
10633PDF: 6383HTML: 21789 -
ASSESSMENT OF CONGENITAL NEUTROPENIA IN CHILDREN: COMMON CLINICAL SCENERIES AND CLUES FOR MANAGEMENT Assessment of congenital neutropenia in children
2005PDF: 1143HTML: 629 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2215PDF: 1500HTML: 268 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3244PDF: 1337HTML: 4131 -
NOVEL MUTATIONS IN THE NON-STRUCTURE PROTEIN 2 OF SARS-CoV-2 Sequence analysis NSP2 of SARS-CoV-2
961PDF: 461HTML: 119 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1680PDF: 1183HTML: 226 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2381PDF: 999HTML: 1648Fig 1: 186Tab I: 213Cover Letter: 206 -
MENDELIAN SUSCEPTIBILITY TO MYCOBACTERIAL DISEASE IN EGYPTIAN CHILDREN
1795PDF: 836HTML: 1150Cover: 182 -
IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
2227PDF: 965HTML: 1899 -
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19
3271PDF: 1538HTML: 446 -
DISSEMINATED HISTOPLASMOSIS AS AIDS PRESENTATION. CASE REPORT AND COMPREHENSIVE REVIEW OF CURRENT LITERATURE
3688PDF: 1286HTML: 729Figure 2: 453Figure 1: 3119 -
HEMATOLOGY PATIENT PROTECTION DURING THE COVID-19 PANDEMIC IN ITALY: A NATIONWIDE NURSING SURVEY Hematology patient protection during the COVID-19
1613PDF: 584HTML: 229 -
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
2766PDF: 1012HTML: 412TABLE: 192FIGURES: 254 -
HISTORY OF ACUTE PROMYELOCYTIC LEUKEMIA: A TALE OF ENDLESS REVOLUTION
3168PDF: 1116HTML: 1764 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
945PDF: 518HTML: 194 -
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
2145PDF: 611Suppl. Files: 283HTML: 172 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2141PDF: 1323HTML: 3501 -
How I treat acute and persistent sickle cell pain
1936PDF: 1119HTML: 485 -
ROLE OF CYTOKINES AS MOLECULAR MARKER OF DENGUE SEVERITY
3179PDF: 1152HTML: 395 -
IDENTİFİCATİON OF LEİSHMANİA TROPİCA FROM PEDİATRİC VİSCERAL LEİSHMANİASİS İN SOUTHERN MEDITERRANEAN REGION OF TURKEY. Molecular characterization of pediatric visceral leishmaniasis
1008PDF: 696HTML: 222 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
17PDF: 8HTML: 0 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3071PDF: 878HTML: 7164Kost Fig1: 185Kost Fig 2: 180Kost Fig3: 177Kost Fig 4: 191Kost Fig5: 186Kost fig 6: 174 -
-
SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE COVID-19 and Hematology
1078PDF: 962HTML: 328







